GSK Champions More Trial Data Disclosure, But PhRMA Objects
In its latest move on the transparency front, Glaxo endorses the U.K.-driven AllTrials campaign, which calls for releasing all clinical trial results. Announcement runs counter to PhRMA’s defense against requirements for more disclosure.
You may also be interested in...
European Notebook: EMA Conflict Of Interest Rules; EU Unitary Patent; EMA Adverse Event Literature Screening
EMA tightens rules on the revolving door between industry and scientific (if not regulators); the European unitary patent proposal survives Spain's judicial challenge; Switzerland amends its drug pricing procedures, and more in this month's column.
JAMA studies focus on the high number of terminated and unreported trials, plus discrepancies in publicly reported trial results. Publication comes as the Institute of Medicine consults stakeholders about trial data sharing and ahead of new reporting laws in Europe.
Influential U.K. parliamentary panel keeps the pressure up on making clinical trial data more widely available, including greater sharing between regulators and health technology assessors.